SCHEMBL4160200

SCHEMBL4160200

Cc1ccc(C(=O)N2CCCC2)c(C)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.58
KMT2A Q03164 3/20 0.58
HTT P42858 2/20 0.57
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
KDM4E B2RXH2 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
LMNA P02545 1/20 0.52
TSHR P16473 1/20 0.51
L3MBTL3 Q96JM7 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ALDH1A1 P00352 2/20 0.51
GLA P06280 1/20 0.51
MAPT P10636 1/20 0.51
MCL1 Q07820 1/20 0.51
HCRTR1 O43613 1/20 0.51
HCRTR2 O43614 1/20 0.51
MEN1 O00255 1/20 0.50
GAA P10253 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24016907 0.98 KMT2A (0.60) HPGDKMT2AHTTNPC1RAB9A
SCHEMBL15692312 0.96 HTT (0.62) HPGDKMT2AHTTNPC1RAB9A
SCHEMBL11961209 0.86 HRH4 (0.54) HPGDKMT2AHTTKDM4ESMN1; SMN2
SCHEMBL24910640 0.86 LMNA (0.53) HPGDKMT2AHTTKDM4ESMN1; SMN2
SCHEMBL12846473 0.86 HPGD (0.58) HPGDKMT2AHTTNPC1RAB9A
SCHEMBL11960910 0.85 RAB9A (0.58) HPGDHTTNPC1RAB9AKDM4E
SCHEMBL20460441 0.85 RXFP1 (0.50) HPGDKMT2AHTTKDM4ESMN1; SMN2
SCHEMBL15306495 0.84 HPGD (0.57) HPGDKMT2AHTTNPC1RAB9A
SCHEMBL25330986 0.83 HSP90AA1 (0.49) HPGDKMT2AHTTKDM4ESMN1; SMN2
SCHEMBL13504106 0.83 HPGD (0.61) HPGDKMT2AHTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-12-10 US disclosed
US-9102625-B2 Nicotinamides as JAK kinase modulators PORTOLA PHARMACEUTICALS, INC. (US) 2015-08-11 US disclosed
US-20090105292-A9 Glucocorticoid Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-04-23 US disclosed
US-20070281959-A1 Glucocorticoid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2007-12-06 US disclosed
EP-1718653-A1 GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY Ligand Pharmaceuticals Inc. (US) 2006-11-08 EP disclosed
WO-2005082909-A1 GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY LIGAND PHARMACEUTICALS INCORPORATED (US) 2005-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK HPGD 49/4885KMT2A 1713/4885HTT 1328/4885
US-20090105292-A9 Glucocorticoid Receptor Modulator Compounds and Methods NR3C1, NR3C2, MC2R HPGD 272/4885KMT2A 4088/4885HTT 4858/4885
US-20070281959-A1 Glucocorticoid receptor modulator compounds and methods NR3C1, NR3C2, MC2R HPGD 272/4885KMT2A 4088/4885HTT 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.